EP2248812A3 - Kondensierte cyclische verbindungen als gpr40 modulatoren - Google Patents

Kondensierte cyclische verbindungen als gpr40 modulatoren Download PDF

Info

Publication number: EP2248812A3
Authority: EP; European Patent Office
Prior art keywords: receptor modulators; cyclic compounds; fused cyclic; gpr40 receptor; inhibitor
Prior art date: 2006-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP10172951A

Other languages

English (en)

French (fr)

Other versions

EP2248812B1 (de

EP2248812A2 (de

Inventor

Tsuneo Yasuma

Nobuyuki Negoro

Masayuki Yamashita

Masahiro Itou

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-27

Filing date

2007-06-26

Publication date

2011-03-16

2007-06-26 Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd

2007-06-26 Priority to SI200731426T priority Critical patent/SI2248812T1/sl

2007-06-26 Priority to PL10172951T priority patent/PL2248812T3/pl

2010-11-10 Publication of EP2248812A2 publication Critical patent/EP2248812A2/de

2011-03-16 Publication of EP2248812A3 publication Critical patent/EP2248812A3/de

2013-12-25 Application granted granted Critical

2013-12-25 Publication of EP2248812B1 publication Critical patent/EP2248812B1/de

2014-03-18 Priority to CY20141100213T priority patent/CY1114978T1/el

Status Active legal-status Critical Current

2027-06-26 Anticipated expiration legal-status Critical

Links

150000001923 cyclic compounds Chemical class 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
229940123208 Biguanide Drugs 0.000 abstract 1
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 abstract 1
229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 abstract 1
102100023915 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
229940100389 Sulfonylurea Drugs 0.000 abstract 1
239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
229960003365 mitiglinide Drugs 0.000 abstract 1
WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 abstract 1
229960000698 nateglinide Drugs 0.000 abstract 1
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Dermatology (AREA)

EP10172951.5A 2006-06-27 2007-06-26 Kondensierte cyclische verbindungen als gpr40 modulatoren Active EP2248812B1 (de)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
SI200731426T SI2248812T1 (sl)	2006-06-27	2007-06-26	Kondenzirane ciklične spojine kot modulatorji GPR40 receptorja
PL10172951T PL2248812T3 (pl)	2006-06-27	2007-06-26	Sprzężone związki cykliczne jako modulatory receptora GPR40
CY20141100213T CY1114978T1 (el)	2006-06-27	2014-03-18	Συντηγμενες κυκλικες ενωσεις ως ρυθμιστες υποδοχεα gpr40

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2006177099		2006-06-27
EP07767983A EP2041123B9 (de)	2006-06-27	2007-06-26	Kondensierte cyclische verbindungen

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
EP07767983.5 Division		2007-06-26

Publications (3)

Publication Number	Publication Date
EP2248812A2 EP2248812A2 (de)	2010-11-10
EP2248812A3 true EP2248812A3 (de)	2011-03-16
EP2248812B1 EP2248812B1 (de)	2013-12-25

Family

ID=38656568

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
EP07767983A Active EP2041123B9 (de)	2006-06-27	2007-06-26	Kondensierte cyclische verbindungen
EP11194016A Withdrawn EP2431367A3 (de)	2006-06-27	2007-06-26	Kondensierte cyclische Verbindungen als GPR40 Modulatoren
EP10172951.5A Active EP2248812B1 (de)	2006-06-27	2007-06-26	Kondensierte cyclische verbindungen als gpr40 modulatoren
EP13190005.2A Withdrawn EP2743268A3 (de)	2006-06-27	2007-06-26	Kondensierte zyklische Verbindungen als GPR40 Modulatoren

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
EP07767983A Active EP2041123B9 (de)	2006-06-27	2007-06-26	Kondensierte cyclische verbindungen
EP11194016A Withdrawn EP2431367A3 (de)	2006-06-27	2007-06-26	Kondensierte cyclische Verbindungen als GPR40 Modulatoren

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP13190005.2A Withdrawn EP2743268A3 (de)	2006-06-27	2007-06-26	Kondensierte zyklische Verbindungen als GPR40 Modulatoren

Country Status (36)

Country	Link
US (5)	US7732626B2 (de)
EP (4)	EP2041123B9 (de)
JP (3)	JP4401428B2 (de)
KR (1)	KR101058772B1 (de)
CN (4)	CN103083307A (de)
AR (1)	AR061644A1 (de)
AT (1)	ATE543815T1 (de)
AU (1)	AU2007265966B2 (de)
BR (1)	BRPI0713378A8 (de)
CA (2)	CA2838448A1 (de)
CL (1)	CL2007001873A1 (de)
CO (1)	CO6160234A2 (de)
CR (1)	CR10564A (de)
CY (2)	CY1112705T1 (de)
DK (2)	DK2041123T3 (de)
ES (2)	ES2450081T3 (de)
GE (1)	GEP20115359B (de)
HR (2)	HRP20120333T1 (de)
IL (1)	IL195947A (de)
JO (1)	JO2969B1 (de)
MA (1)	MA30537B1 (de)
ME (1)	ME00535B (de)
MX (1)	MX2008016274A (de)
MY (1)	MY154798A (de)
NO (1)	NO20090235L (de)
NZ (1)	NZ574038A (de)
PE (1)	PE20080993A1 (de)
PL (2)	PL2041123T3 (de)
PT (2)	PT2041123E (de)
RS (2)	RS52307B (de)
RU (1)	RU2444521C2 (de)
SI (2)	SI2041123T1 (de)
TW (1)	TWI354668B (de)
UA (1)	UA95296C2 (de)
WO (1)	WO2008001931A2 (de)
ZA (1)	ZA200900154B (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5591706B2 (ja)	2007-10-10	2014-09-17	アムジエン・インコーポレーテツド	置換ビフェニルｇｐｒ４０調節因子
WO2009111056A1 (en) *	2008-03-06	2009-09-11	Amgen Inc.	Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
WO2009117421A2 (en) *	2008-03-17	2009-09-24	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
JP2012503595A (ja)	2008-07-28	2012-02-09	シダンスクユニバーシティ	代謝病の治療用の化合物
TW201014850A (en)	2008-09-25	2010-04-16	Takeda Pharmaceutical	Solid pharmaceutical composition
AU2009303475B2 (en)	2008-10-15	2012-09-13	Amgen Inc.	Spirocyclic GPR40 modulators
JP5535931B2 (ja)	2008-10-27	2014-07-02	武田薬品工業株式会社	二環性化合物
AR074760A1 (es)	2008-12-18	2011-02-09	Metabolex Inc	Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8557805B2 (en)	2008-12-29	2013-10-15	Takeda Pharmaceutical Company Limited	Fused ring compound and use thereof
UY32395A (es)	2009-01-27	2010-08-31	Takeda Pharmaceutical	Compuesto con anillo fusionado y su uso
KR20120022801A (ko)	2009-04-22	2012-03-12	아스텔라스세이야쿠 가부시키가이샤	카르복실산 화합물
US20120172351A1 (en)	2009-06-09	2012-07-05	Nobuyuki Negoro	Novel fused cyclic compound and use thereof
CN102548556A (zh)	2009-07-28	2012-07-04	武田药品工业株式会社	片剂
CA2779398A1 (en)	2009-10-30	2011-05-05	Mochida Phamaceutical Co., Ltd.	Novel 3-hydroxy-5-arylisoxazole derivative
PH12012501456A1 (en)	2009-12-25	2012-10-29	Mochida Pharm Co Ltd	Novel 3-hydroxy -5- arylisothiazole derivative
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
UY33354A (es)	2010-04-27	2011-12-01	Takeda Pharmaceutical	Compuesto biciclico como inhibidor acc
US8299117B2 (en)	2010-06-16	2012-10-30	Metabolex Inc.	GPR120 receptor agonists and uses thereof
CN103068816B (zh)	2010-06-16	2015-01-07	武田药品工业株式会社	酰胺化合物的结晶
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012036293A1 (ja)	2010-09-17	2012-03-22	武田薬品工業株式会社	糖尿病治療剤
AU2011313191A1 (en)	2010-10-08	2013-05-02	Mochida Pharmaceutical Co., Ltd.	Cyclic amide derivative
US8729102B2 (en)	2010-11-30	2014-05-20	Takeda Pharmaceutical Company Limited	Bicyclic compound
EP2646425B1 (de)	2010-12-01	2015-06-10	Boehringer Ingelheim International Gmbh	Zur Behandlung des metabolischen Syndroms geeignete Indanyloxydihydrobenzofuranylessigsäuren
UY33913A (es)	2011-02-17	2012-09-28	Takeda Pharmaceutical	Método de producción de derivado de dihidrobenzofurano ópticamente activo
WO2012136221A1 (en)	2011-04-08	2012-10-11	Syddansk Universitet	Ortho-fluoro substituted compounds for the treatment of metabolic diseases
AR085990A1 (es)	2011-04-27	2013-11-13	Mochida Pharm Co Ltd	Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen
JPWO2012147516A1 (ja)	2011-04-28	2014-07-28	持田製薬株式会社	環状アミド誘導体
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103012343B (zh) *	2011-09-26	2015-04-08	上海恒瑞医药有限公司	稠合环类衍生物、其制备方法及其在医药上的应用
EP2760862B1 (de)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
JPWO2013061962A1 (ja)	2011-10-24	2015-04-02	武田薬品工業株式会社	二環性化合物
EP2803664B1 (de) *	2012-01-12	2018-11-21	Jiangsu Hengrui Medicine Co. Ltd.	Tetrahydrobenzofuran abkömmlinge als gpr40 agonisten zur behandlung von diabetes
US9365540B2 (en)	2012-01-12	2016-06-14	Takeda Pharmaceutical Company Limited	Benzimidazole derivatives as MCH receptor antagonists
GB2498968A (en) *	2012-02-01	2013-08-07	Prosidion Ltd	Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist
WO2013122029A1 (ja)	2012-02-13	2013-08-22	武田薬品工業株式会社	芳香環化合物
EP2816023A4 (de)	2012-02-13	2015-09-09	Takeda Pharmaceutical	Aromatische ringverbindung
EP2814466B1 (de)	2012-02-15	2018-12-26	Takeda Pharmaceutical Company Limited	Tablette enthaltend 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamid oder ein salz davon
JP6106179B2 (ja) *	2012-02-24	2017-03-29	武田薬品工業株式会社	芳香環化合物
TW201341356A (zh) *	2012-02-28	2013-10-16	皮拉馬爾企業有限公司	作為gpr促效劑之苯基烷酸衍生物
US8642585B2 (en) *	2012-03-26	2014-02-04	Boehringer Ingelheim International Gmbh	Indanyloxydihydrobenzofuranylacetic acids
CN104350040B (zh)	2012-03-29	2016-06-01	武田药品工业株式会社	芳环化合物
US8809376B2 (en) *	2012-04-30	2014-08-19	Boehringer Ingelheim International Gmbh	Indanyloxydihydrobenzofuranylacetic acids
WO2013168759A1 (ja)	2012-05-10	2013-11-14	武田薬品工業株式会社	芳香環化合物
US9505772B2 (en)	2012-05-10	2016-11-29	Takeda Pharmaceutical Company Limited	Aromatic ring compound
JP6122879B2 (ja)	2012-06-05	2017-04-26	武田薬品工業株式会社	固形製剤
AU2013290100A1 (en)	2012-07-11	2015-01-29	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2015127299A (ja)	2012-07-19	2015-07-09	武田薬品工業株式会社	固形製剤
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
SI2894151T1 (sl)	2012-09-04	2021-01-29	Shanghai Hengrui Pharmaceutical Co. Ltd.	Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini
CN105142621A (zh)	2012-10-24	2015-12-09	国家健康科学研究所	用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
TWI692469B (zh) *	2012-11-09	2020-05-01	南韓商Ｌｇ化學股份有限公司	Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
UY35143A (es)	2012-11-16	2014-05-30	Bristol Myers Squibb Co	Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
HK1210144A1 (en)	2012-11-28	2016-04-15	勃林格殷格翰国际有限公司	New indanyloxydihydrobenzofuranylacetic acids
JP6283862B2 (ja) *	2012-12-07	2018-02-28	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規インダニルオキシジヒドロベンゾフラニル酢酸
JP6314335B2 (ja)	2013-02-06	2018-04-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新しいインダニルオキシジヒドロベンゾフラニル酢酸
JP2016516004A (ja)	2013-02-22	2016-06-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病二環式化合物
AU2014221489B2 (en)	2013-02-28	2018-03-08	Tiumbio Co., Ltd.	Tricyclic compound and use thereof
CN103145663B (zh) *	2013-03-01	2016-03-23	上海高准医药有限公司	(s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用
US9605000B2 (en)	2013-03-14	2017-03-28	Takeda Pharmaceutical Company Limited	Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
CN104059039B (zh) *	2013-03-22	2017-03-15	正大天晴药业集团股份有限公司	具有gpr40受体功能调节作用的稠环化合物
US10005720B2 (en)	2013-04-05	2018-06-26	North Carolina Central University	Compounds useful for the treatment of metabolic disorders and synthesis of the same
WO2014170842A2 (en)	2013-04-17	2014-10-23	Piramal Enterprises Limited	Substituted alkyl carboxylic acid derivatives as gpr agonists
CN104870429B (zh) *	2013-05-22	2017-05-03	四川海思科制药有限公司	苯并呋喃衍生物、其制备方法及其在医药上的应用
CN104250238B (zh) *	2013-06-25	2017-12-26	南京圣和药业股份有限公司	Gpr40激动剂及其应用
CN104250239B (zh) *	2013-06-29	2016-09-07	山东轩竹医药科技有限公司	芳香多环羧酸衍生物
WO2015000412A1 (zh) *	2013-07-02	2015-01-08	四川海思科制药有限公司	苯并环丁烯类衍生物、其制备方法及其在医药上的应用
UY35650A (es)	2013-07-09	2015-02-27	Takeda Pharmaceutical	Compuesto heterocíclico
ES2672992T3 (es)	2013-08-09	2018-06-19	Takeda Pharmaceutical Company Limited	Compuesto aromático
CN104370864B (zh) *	2013-08-14	2016-04-13	成都苑东生物制药股份有限公司	一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙腈化合物和以该化合物制备tak-875药物的方法
WO2015032328A1 (zh) *	2013-09-03	2015-03-12	四川海思科制药有限公司	茚满衍生物及其制备方法和在医药上的应用
JO3442B1 (ar)	2013-10-07	2019-10-20	Takeda Pharmaceuticals Co	مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2015062486A1 (en) *	2013-10-31	2015-05-07	Sunshine Lake Pharma Co., Ltd.	Biphenyl compounds and uses thereof
CN105722841A (zh)	2013-11-14	2016-06-29	卡迪拉保健有限公司	新型杂环化合物
US10519115B2 (en)	2013-11-15	2019-12-31	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
CN104650055A (zh) *	2013-11-22	2015-05-27	山东轩竹医药科技有限公司	芳香多环羧酸衍生物
WO2015084692A1 (en)	2013-12-04	2015-06-11	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
WO2015089809A1 (en)	2013-12-19	2015-06-25	Merck Sharp & Dohme Corp.	Antidiabetic substituted heteroaryl compounds
US10059667B2 (en)	2014-02-06	2018-08-28	Merck Sharp & Dohme Corp.	Antidiabetic compounds
US9428470B2 (en)	2014-02-13	2016-08-30	Takeda Pharmaceutical Company Limited	Heterocyclic compound
US9346776B2 (en)	2014-02-13	2016-05-24	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
CN105001212B (zh) *	2014-04-16	2018-01-16	江苏柯菲平医药股份有限公司	稠环化合物及其制备方法和应用
WO2015176267A1 (en)	2014-05-22	2015-11-26	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2016022742A1 (en)	2014-08-08	2016-02-11	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
WO2016022448A1 (en)	2014-08-08	2016-02-11	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
US10100042B2 (en)	2014-08-08	2018-10-16	Merck Sharp & Dohme Corp.	[5,6]—fused bicyclic antidiabetic compounds
WO2016019587A1 (en)	2014-08-08	2016-02-11	Merck Sharp & Dohme Corp.	[7, 6]-fused bicyclic antidiabetic compounds
CN104177320B (zh) *	2014-08-27	2016-03-02	广东东阳光药业有限公司	一种脲取代联苯类化合物及其组合物及用途
CN104193731B (zh) *	2014-08-27	2017-03-15	广东东阳光药业有限公司	一种脲取代联苯类化合物及其组合物及用途
EP3207928B1 (de) *	2014-10-17	2021-03-10	Hyundai Pharm Co., Ltd.	Zusammengesetztes präparat mit einem neuartigen 3-(4-(benzyloxy)phenyl)hex-4-inonensäure-derivat und einem anderen wirkstoff zur vorbeugung oder behandlung von stoffwechselerkrankungen
EP3273981B1 (de)	2015-03-24	2020-04-29	INSERM - Institut National de la Santé et de la Recherche Médicale	Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von diabetes
CN105418563B (zh) *	2015-12-28	2017-11-10	山东大学	Tak‑875类似物及其制备方法与应用
EP3436003B1 (de)	2016-03-29	2023-08-23	Merck Sharp & Dohme LLC	Antidiabetische bicyclische verbindungen
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
JP7050792B2 (ja)	2017-01-26	2022-04-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7049349B2 (ja)	2017-01-26	2022-04-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110198928B (zh)	2017-01-26	2023-08-29	勃林格殷格翰国际有限公司	苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
US10919859B2 (en)	2017-01-26	2021-02-16	Boehringer Ingelheim International Gmbh	Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7049353B2 (ja)	2017-02-08	2022-04-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
AR111307A1 (es)	2017-03-30	2019-06-26	Takeda Pharmaceuticals Co	Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa
US11186565B2 (en)	2017-03-31	2021-11-30	Takeda Pharmaceutical Company Limited	Aromatic compound
JOP20190211A1 (ar)	2017-03-31	2019-09-15	Takeda Pharmaceuticals Co	ببتيد منشط لمستقبل gip
AR111199A1 (es)	2017-03-31	2019-06-12	Takeda Pharmaceuticals Co	Compuesto aromático agonista de gpr40
BR102018007822A2 (pt)	2017-04-20	2018-11-06	Gilead Sciences, Inc.	composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
US11225471B2 (en)	2017-11-16	2022-01-18	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
DK3737470T5 (da)	2018-01-08	2024-05-27	Celon Pharma Sa	3-phenyl-4-hexynsyrederivater som gpr40-agonister
WO2019160882A1 (en)	2018-02-13	2019-08-22	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
CN110294744A (zh) *	2018-03-21	2019-10-01	中国医学科学院药物研究所	Gpr40受体激动剂、其制法和其药物组合物与用途
MX2020009950A (es)	2018-03-23	2021-04-28	Carmot Therapeutics Inc	Moduladores de receptores acoplados a proteina g.
KR102591947B1 (ko)	2018-04-19	2023-10-25	길리애드 사이언시즈, 인코포레이티드	Pd-1/pd-l1 억제제
PE20210642A1 (es)	2018-07-13	2021-03-23	Gilead Sciences Inc	Inhibidores de pd-1/pd-l1
EP3650440A4 (de)	2018-08-27	2020-11-25	Scohia Pharma, Inc.	Benzoeesterverbindung
US20220016215A1 (en)	2018-09-24	2022-01-20	Takeda Phaarmaceutical Company Limited	Gip receptor agonist peptide compounds and uses thereof
EP3856768A2 (de)	2018-09-24	2021-08-04	Takeda Pharmaceutical Company Limited	Gip-rezeptor-agonist-peptidverbindungen und deren verwendungen
US11236085B2 (en)	2018-10-24	2022-02-01	Gilead Sciences, Inc.	PD-1/PD-L1 inhibitors
WO2022034664A1 (ja)	2020-08-12	2022-02-17	株式会社ジェクスヴァル	骨疾患の予防または治療用の医薬組成物
CN113677369A (zh) *	2019-02-13	2021-11-19	嘉惟思远制药有限公司	用于预防或治疗骨疾病的药物组合物
US20220071925A1 (en) *	2019-02-13	2022-03-10	Gexval Inc.	Medicinal composition for preventing or treating bone diseases
PT4097099T (pt)	2020-02-07	2024-07-19	Gasherbrum Bio Inc	Agonistas heterocíclicos de glp-1
IL296219A (en)	2020-03-25	2022-11-01	Takeda Pharmaceuticals Co	Qw dosing of gip receptor agonist peptide compounds and uses thereof
IL296592A (en)	2020-03-25	2022-11-01	Takeda Pharmaceuticals Co	Qd dosing of gip receptor agonist peptide compounds and uses thereof
WO2021219019A1 (en)	2020-04-29	2021-11-04	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
US20240067603A1 (en) *	2020-12-16	2024-02-29	Regents Of The University Of Minnesota	Cubanyl biguanide compounds
KR20240007251A (ko)	2021-05-13	2024-01-16	카모트 테라퓨틱스, 인크.	G-단백질 결합 수용체의 조절제
EP4490155A1 (de)	2022-03-09	2025-01-15	Gasherbrum Bio, Inc.	Heterocyclische glp-1-agonisten
JP2025510741A (ja)	2022-03-21	2025-04-15	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環式ｇｌｐ－１アゴニスト
US20250250269A1 (en)	2022-04-14	2025-08-07	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
CN121002014A (zh)	2022-12-15	2025-11-21	加舒布鲁姆生物公司	具有glp-1激动剂活性的化合物的盐和固体形式
JP2026501285A (ja)	2022-12-22	2026-01-14	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環式ｇｌｐ－１アゴニスト
EP4638455A1 (de)	2022-12-22	2025-10-29	Gasherbrum Bio, Inc.	Heterocyclische glp-1-agonisten
KR20250168210A (ko)	2023-02-16	2025-12-02	가셔브룸 바이오, 인크.	헤테로시클릭 glp-1 효능제
US20250019389A1 (en)	2023-06-30	2025-01-16	Gasherbrum Bio, Inc.	Heterocyclic agonists
JP2026526054A (ja)	2023-07-13	2026-08-04	アコンカグア・バイオ・インコーポレイテッド	化合物、組成物、および方法
EP4743174A1 (de)	2023-07-13	2026-05-20	Aconcagua Bio, Inc.	Modulatoren der aktivität des calcitoninrezeptors und/oder amylinrezeptors
EP4771001A1 (de)	2023-08-31	2026-07-08	Gasherbrum Bio, Inc.	Heteroaryl-heterocycloalkyl-basierte glp-1-agonisten
WO2025137307A1 (en)	2023-12-20	2025-06-26	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
CN117865851A (zh) *	2024-01-10	2024-04-12	上海吉奉生物科技有限公司	一种Fmoc-2,6-二甲基酪氨酸的合成方法
WO2025154021A1 (en)	2024-01-19	2025-07-24	Takeda Pharmaceutical Company Limited	Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en)	2024-01-19	2025-07-24	Takeda Pharmaceutical Company Limited	Improved gip receptor agonist peptide compounds and uses thereof
WO2025171341A2 (en)	2024-02-08	2025-08-14	Aconcagua Bio, Inc.	Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en)	2024-02-08	2025-08-14	Aconcagua Bio, Inc.	The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2026041075A1 (en)	2024-08-21	2026-02-26	Gasherbrum Bio, Inc.	Gpl-1 agonists
WO2026051998A1 (en)	2024-09-04	2026-03-12	Aconcagua Bio, Inc.	Compounds, compositions, and methods
WO2026096926A1 (en)	2024-11-01	2026-05-07	Aconcagua Bio, Inc.	Compounds, compositions, and methods
WO2026156091A1 (en)	2025-01-15	2026-07-23	Aconcagua Bio, Inc.	Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005063729A1 (en) *	2003-12-25	2005-07-14	Takeda Pharmaceutical Company Limited	3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005087710A1 (ja) *	2004-03-15	2005-09-22	Takeda Pharmaceutical Company Limited	アミノフェニルプロパン酸誘導体
EP1630152A1 (de) *	2003-05-30	2006-03-01	Takeda Pharmaceutical Company Limited	Verbindung mit kondensiertem ring

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9309324D0 (en) *	1993-05-06	1993-06-16	Bayer Ag	Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
US5612330A (en)	1994-03-07	1997-03-18	Warner-Lambert Company	Methods for inhibiting and controlling viral growth
US5489586A (en)	1994-03-07	1996-02-06	Warner-Lambert Company	Method for treating inflammatory disease in humans
CN1072649C (zh)	1995-09-13	2001-10-10	武田药品工业株式会社	苯并氧杂吖庚因化合物,其生产方法和用途
US5807876A (en) *	1996-04-23	1998-09-15	Vertex Pharmaceuticals Incorporated	Inhibitors of IMPDH enzyme
RU6023U1 (ru)	1997-01-20	1998-02-16	АО "Автоэлектроника"	Устройство управления для экономайзера принудительного холостого хода
US6025372A (en)	1997-04-04	2000-02-15	Merck & Co., Inc.	Somatostatin agonists
US6057338A (en)	1997-04-04	2000-05-02	Merck & Co., Inc.	Somatostatin agonists
AU1285499A (en)	1997-10-30	1999-05-24	Merck & Co., Inc.	Somatostatin agonists
NZ515087A (en)	1999-04-28	2003-11-28	Aventis Pharma Gmbh	Tri-aryl acid derivatives as PPAR receptor ligands
RU11297U1 (ru)	1999-06-16	1999-09-16	Курзанов Евгений Владимирович	Установка для выборочного измерения производительности нефтяных источников при групповом учете
AR035016A1 (es)	1999-08-25	2004-04-14	Takeda Chemical Industries Ltd	Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ES2250196T3 (es)	1999-08-26	2006-04-16	Aventis Pharmaceuticals Inc.	Aminoiminometil o aminometil dihidrobenzofuranos y benzopiranos sustituidos.
AU7556800A (en)	1999-10-07	2001-05-10	Tadeka Chemical Industries, Ltd.	Amine derivatives
CA2390923A1 (en)	1999-11-10	2001-05-31	Takeda Chemical Industries, Ltd.	5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
DE60018216T2 (de) *	1999-12-24	2006-02-16	Kyowa Hakko Kogyo Co., Ltd.	Kondensierte purinderivate
PT1285651E (pt)	2000-04-28	2010-10-21	Takeda Pharmaceutical	Antagonistas da hormona concentradora da melanina
EP1283199A4 (de)	2000-05-16	2003-12-17	Takeda Chemical Industries Ltd	Antagonisten des melanin-konzentrierenden hormons
US6429223B1 (en) *	2000-06-23	2002-08-06	Medinox, Inc.	Modified forms of pharmacologically active agents and uses therefor
RU2340611C2 (ru)	2000-09-15	2008-12-10	Вертекс Фармасьютикалз Инкорпорейтед	Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) *	2000-09-15	2002-03-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) *	2000-09-15	2003-09-02	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) *	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
WO2002068471A2 (en) *	2000-12-21	2002-09-06	Bristol-Myers Squibb Company	Nucleic acid molecules and polypeptides for a human cation channel polypeptide
BR0116493A (pt)	2000-12-21	2003-09-30	Vertex Pharma	Compostos de pirazol úteis como inibidores de proteìna cinase
GEP20053675B (en) *	2001-03-30	2005-11-25	Pfizer Prod Inc	Pyridazinone Aldose Reductase Inhibitors
TWI311133B (en) *	2001-04-20	2009-06-21	Eisai R&D Man Co Ltd	Carboxylic acid derivativeand the salt thereof
TW522326B (en) *	2001-08-03	2003-03-01	Inventec Corp	Real-time data customer service system and method thereof
US6701066B2 (en) *	2001-10-11	2004-03-02	Micron Technology, Inc.	Delivery of solid chemical precursors
WO2003042204A1 (en)	2001-10-19	2003-05-22	Takeda Chemical Industries, Ltd.	Amine derivative
JP4166024B2 (ja)	2002-03-07	2008-10-15	独立行政法人科学技術振興機構	２環式化合物およびその製造方法
BR0309546A (pt) *	2002-04-26	2005-02-15	Hoffmann La Roche	Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
AU2003252697A1 (en) *	2002-07-26	2004-02-16	Kyowa Hakko Kogyo Co., Ltd.	Cell differentiation inductor
AU2003277576A1 (en)	2002-11-08	2004-06-07	Takeda Pharmaceutical Company Limited	Receptor function controlling agent
US7572910B2 (en) *	2003-02-20	2009-08-11	Pfizer, Inc.	Pyridazinone aldose reductase inhibitors
JPWO2004080943A1 (ja) *	2003-03-11	2006-06-08	小野薬品工業株式会社	シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
US7244763B2 (en)	2003-04-17	2007-07-17	Warner Lambert Company Llc	Compounds that modulate PPAR activity and methods of preparation
JP4805552B2 (ja) *	2003-05-30	2011-11-02	武田薬品工業株式会社	縮合環化合物
RU2353617C2 (ru)	2003-10-31	2009-04-27	Такеда Фармасьютикал Компани Лимитед	Производные пиридина в качестве ингибиторов дипептидилпептидазы iv
TW200523252A (en) *	2003-10-31	2005-07-16	Takeda Pharmaceutical	Pyridine compounds
WO2005051890A1 (en)	2003-11-19	2005-06-09	Smithkline Beecham Corporation	Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
JP4074616B2 (ja) *	2003-12-25	2008-04-09	武田薬品工業株式会社	３−（４−ベンジルオキシフェニル）プロパン酸誘導体
WO2005063725A1 (ja) *	2003-12-26	2005-07-14	Takeda Pharmaceutical Company Limited	フェニルプロパン酸誘導体
JP4859665B2 (ja) *	2004-03-30	2012-01-25	武田薬品工業株式会社	アルコキシフェニルプロパン酸誘導体
UA90269C2 (ru) *	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Тетрагидрохинолиновые производные и способ их получения
TW200609219A (en) *	2004-06-17	2006-03-16	Neurogen Corp	Aryl-substituted piperazine derivatives
JP3689711B1 (ja)	2004-12-24	2005-08-31	極東鋼弦コンクリート振興株式会社	真空グラウト注入方法
TW200637839A (en) *	2005-01-07	2006-11-01	Taisho Pharmaceutical Co Ltd	1-thio-d-glucitol derivatives
ZA200708144B (en) *	2005-02-25	2008-11-26	Takeda Pharmaceutical	Pyridyl acetic acid compounds
TW200815418A (en) *	2006-06-27	2008-04-01	Astrazeneca Ab	New compounds I
TW200811170A (en) *	2006-06-27	2008-03-01	Sanofi Aventis	Urea derivatives of tropane, their preparation and their therapeutic application
TW200811158A (en) *	2006-06-27	2008-03-01	Sanofi Aventis	Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application

2007
- 2007-06-26 AU AU2007265966A patent/AU2007265966B2/en not_active Ceased
- 2007-06-26 US US12/308,699 patent/US7732626B2/en active Active
- 2007-06-26 TW TW096122999A patent/TWI354668B/zh not_active IP Right Cessation
- 2007-06-26 MX MX2008016274A patent/MX2008016274A/es active IP Right Grant
- 2007-06-26 ES ES10172951.5T patent/ES2450081T3/es active Active
- 2007-06-26 CA CA2838448A patent/CA2838448A1/en not_active Abandoned
- 2007-06-26 EP EP07767983A patent/EP2041123B9/de active Active
- 2007-06-26 EP EP11194016A patent/EP2431367A3/de not_active Withdrawn
- 2007-06-26 NZ NZ574038A patent/NZ574038A/en not_active IP Right Cessation
- 2007-06-26 ME MEP-2008-901A patent/ME00535B/me unknown
- 2007-06-26 PT PT07767983T patent/PT2041123E/pt unknown
- 2007-06-26 CN CN2012105303764A patent/CN103083307A/zh active Pending
- 2007-06-26 CN CN2007800320224A patent/CN101616913B/zh not_active Expired - Fee Related
- 2007-06-26 PL PL07767983T patent/PL2041123T3/pl unknown
- 2007-06-26 SI SI200730892T patent/SI2041123T1/sl unknown
- 2007-06-26 CN CN2012105303389A patent/CN103070854A/zh active Pending
- 2007-06-26 RS RS20120169A patent/RS52307B/sr unknown
- 2007-06-26 MY MYPI20085345A patent/MY154798A/en unknown
- 2007-06-26 EP EP10172951.5A patent/EP2248812B1/de active Active
- 2007-06-26 AT AT07767983T patent/ATE543815T1/de active
- 2007-06-26 ZA ZA200900154A patent/ZA200900154B/xx unknown
- 2007-06-26 PL PL10172951T patent/PL2248812T3/pl unknown
- 2007-06-26 CA CA2656003A patent/CA2656003C/en active Active
- 2007-06-26 BR BRPI0713378A patent/BRPI0713378A8/pt not_active IP Right Cessation
- 2007-06-26 GE GEAP200711077A patent/GEP20115359B/en unknown
- 2007-06-26 KR KR1020097001696A patent/KR101058772B1/ko not_active Expired - Fee Related
- 2007-06-26 WO PCT/JP2007/063208 patent/WO2008001931A2/en not_active Ceased
- 2007-06-26 CN CN201210241482.0A patent/CN102731451B/zh not_active Expired - Fee Related
- 2007-06-26 RS RS20140115A patent/RS53230B/sr unknown
- 2007-06-26 JO JO2007260A patent/JO2969B1/en active
- 2007-06-26 EP EP13190005.2A patent/EP2743268A3/de not_active Withdrawn
- 2007-06-26 AR ARP070102823A patent/AR061644A1/es unknown
- 2007-06-26 SI SI200731426T patent/SI2248812T1/sl unknown
- 2007-06-26 ES ES07767983T patent/ES2379661T3/es active Active
- 2007-06-26 CL CL2007001873A patent/CL2007001873A1/es unknown
- 2007-06-26 RU RU2009102515/04A patent/RU2444521C2/ru active
- 2007-06-26 HR HRP20120333TT patent/HRP20120333T1/hr unknown
- 2007-06-26 PE PE2007000827A patent/PE20080993A1/es not_active Application Discontinuation
- 2007-06-26 PT PT101729515T patent/PT2248812E/pt unknown
- 2007-06-26 DK DK07767983.5T patent/DK2041123T3/da active
- 2007-06-26 UA UAA200900604A patent/UA95296C2/uk unknown
- 2007-06-26 JP JP2008554357A patent/JP4401428B2/ja not_active Expired - Fee Related
- 2007-06-26 DK DK10172951.5T patent/DK2248812T5/da active
2008
- 2008-12-15 IL IL195947A patent/IL195947A/en not_active IP Right Cessation
- 2008-12-30 MA MA31524A patent/MA30537B1/fr unknown
2009
- 2009-01-14 NO NO20090235A patent/NO20090235L/no unknown
- 2009-01-16 CR CR10564A patent/CR10564A/es not_active IP Right Cessation
- 2009-01-26 CO CO09006709A patent/CO6160234A2/es unknown
- 2009-07-16 JP JP2009168271A patent/JP4917634B2/ja not_active Expired - Fee Related
2010
- 2010-03-17 US US12/659,695 patent/US8088821B2/en not_active Expired - Fee Related
2011
- 2011-11-02 US US13/287,639 patent/US8492430B2/en not_active Expired - Fee Related
- 2011-12-08 JP JP2011269300A patent/JP5409757B2/ja not_active Expired - Fee Related
2012
- 2012-04-25 CY CY20121100396T patent/CY1112705T1/el unknown
2013
- 2013-06-05 US US13/910,374 patent/US8598226B2/en not_active Expired - Fee Related
- 2013-10-25 US US14/063,100 patent/US20140080891A1/en not_active Abandoned
2014
- 2014-03-05 HR HRP20140201TT patent/HRP20140201T1/hr unknown
- 2014-03-18 CY CY20141100213T patent/CY1114978T1/el unknown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1630152A1 (de) *	2003-05-30	2006-03-01	Takeda Pharmaceutical Company Limited	Verbindung mit kondensiertem ring
WO2005063729A1 (en) *	2003-12-25	2005-07-14	Takeda Pharmaceutical Company Limited	3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005087710A1 (ja) *	2004-03-15	2005-09-22	Takeda Pharmaceutical Company Limited	アミノフェニルプロパン酸誘導体
EP1726580A1 (de) *	2004-03-15	2006-11-29	Takeda Pharmaceutical Company Limited	Aminophenylpropansäurederivat

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRALDI O ET AL: "ELECTRON IMPACT MASS SPECTROMETRY OF SOME 2,3-DIHYDRO-1-BENZOFURAN-3- ACETIC ACIDS", OMS. ORGANIC MASS SPECTROMETRY, WILEY, CHICHESTER, GB LNKD- DOI:10.1002/OMS.1210200112, vol. 20, no. 1, 1 January 1985 (1985-01-01), pages 53 - 57, XP002460665, ISSN: 0030-493X *

Also Published As

Publication number	Publication date
US8088821B2 (en)	2012-01-03
JP2012062320A (ja)	2012-03-29
CO6160234A2 (es)	2010-05-20
US20140080891A1 (en)	2014-03-20
US20100004312A1 (en)	2010-01-07
US7732626B2 (en)	2010-06-08
ME00535B (me)	2011-10-10
EP2743268A2 (de)	2014-06-18
AU2007265966B2 (en)	2012-05-17
KR101058772B1 (ko)	2011-08-24
EP2041123A2 (de)	2009-04-01
HRP20140201T1 (hr)	2014-04-11
ES2379661T3 (es)	2012-04-30
BRPI0713378A8 (pt)	2018-01-02
PE20080993A1 (es)	2008-10-06
UA95296C2 (uk)	2011-07-25
EP2431367A3 (de)	2012-07-04
GEP20115359B (en)	2011-12-26
CR10564A (es)	2012-06-18
SI2248812T1 (sl)	2014-04-30
WO2008001931A3 (en)	2009-09-11
MX2008016274A (es)	2009-01-15
EP2248812B1 (de)	2013-12-25
CN102731451A (zh)	2012-10-17
IL195947A (en)	2013-07-31
US20100197761A1 (en)	2010-08-05
PL2041123T3 (pl)	2012-09-28
US8598226B2 (en)	2013-12-03
RS52307B (sr)	2012-12-31
CA2656003C (en)	2014-03-25
MA30537B1 (fr)	2009-06-01
ATE543815T1 (de)	2012-02-15
JP4917634B2 (ja)	2012-04-18
EP2041123B1 (de)	2012-02-01
NO20090235L (no)	2009-02-16
PT2041123E (pt)	2012-04-09
TWI354668B (en)	2011-12-21
NZ574038A (en)	2011-12-22
EP2743268A3 (de)	2014-10-08
HK1131126A1 (en)	2010-01-15
DK2041123T3 (da)	2012-05-07
CN101616913B (zh)	2013-01-23
CA2656003A1 (en)	2008-01-03
EP2248812A2 (de)	2010-11-10
CY1112705T1 (el)	2016-02-10
PT2248812E (pt)	2014-03-12
AU2007265966A1 (en)	2008-01-03
US20120046338A1 (en)	2012-02-23
MY154798A (en)	2015-07-31
JO2969B1 (en)	2016-03-15
EP2431367A2 (de)	2012-03-21
ES2450081T3 (es)	2014-03-21
ZA200900154B (en)	2010-03-31
RS53230B (sr)	2014-08-29
CN101616913A (zh)	2009-12-30
US8492430B2 (en)	2013-07-23
IL195947A0 (en)	2009-09-01
CY1114978T1 (el)	2016-12-14
CL2007001873A1 (es)	2008-01-04
DK2248812T3 (da)	2014-03-10
JP4401428B2 (ja)	2010-01-20
KR20090027743A (ko)	2009-03-17
HRP20120333T1 (hr)	2012-05-31
JP5409757B2 (ja)	2014-02-05
CA2838448A1 (en)	2008-01-03
CN102731451B (zh)	2015-07-29
CN103070854A (zh)	2013-05-01
AR061644A1 (es)	2008-09-10
DK2248812T5 (da)	2015-01-26
EP2041123B9 (de)	2013-01-02
RU2009102515A (ru)	2010-08-10
WO2008001931A2 (en)	2008-01-03
SI2041123T1 (sl)	2012-05-31
BRPI0713378A2 (pt)	2012-04-03
JP2009280595A (ja)	2009-12-03
PL2248812T3 (pl)	2014-07-31
TW200811125A (en)	2008-03-01
US20130267589A1 (en)	2013-10-10
CN103083307A (zh)	2013-05-08
RU2444521C2 (ru)	2012-03-10
JP2009542580A (ja)	2009-12-03

Legal Events

Date	Code	Title	Description
2010-10-08	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2010-11-10	AC	Divisional application: reference to earlier application	Ref document number: 2041123 Country of ref document: EP Kind code of ref document: P
2010-11-10	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
2010-11-10	AX	Request for extension of the european patent	Extension state: AL BA HR MK RS
2011-02-11	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2011-03-16	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
2011-03-16	AX	Request for extension of the european patent	Extension state: AL BA HR MK RS
2011-03-16	RTI1	Title (correction)	Free format text: FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS
2011-03-23	RTI1	Title (correction)	Free format text: FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS
2011-10-26	17P	Request for examination filed	Effective date: 20110914
2011-12-30	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1150448 Country of ref document: HK
2013-06-21	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2013-06-21	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2013-06-26	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2013-06-26	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 3/10 20060101ALI20130517BHEP Ipc: A61K 31/192 20060101ALI20130517BHEP Ipc: C07D 409/12 20060101AFI20130517BHEP
2013-07-02	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2013-07-09	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2013-07-31	INTG	Intention to grant announced	Effective date: 20130627
2013-08-07	INTG	Intention to grant announced	Effective date: 20130710
2013-11-20	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2013-11-22	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2013-12-25	AC	Divisional application: reference to earlier application	Ref document number: 2041123 Country of ref document: EP Kind code of ref document: P
2013-12-25	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
2013-12-25	AX	Request for extension of the european patent	Extension state: AL BA HR MK RS
2013-12-25	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2013-12-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2014-01-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 646585 Country of ref document: AT Kind code of ref document: T Effective date: 20140115
2014-01-29	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2014-02-13	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602007034515 Country of ref document: DE Effective date: 20140213
2014-02-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG ERFINDER Ref country code: CH Ref legal event code: NV Representative=s name: BOHEST AG, CH
2014-03-05	REG	Reference to a national code	Ref country code: HR Ref legal event code: TUEP Ref document number: P20140201 Country of ref document: HR Ref country code: RO Ref legal event code: EPE
2014-03-10	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20140304
2014-03-12	REG	Reference to a national code	Ref country code: NL Ref legal event code: T3 Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20140305
2014-03-21	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2450081 Country of ref document: ES Kind code of ref document: T3 Effective date: 20140321
2014-03-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R083 Ref document number: 602007034515 Country of ref document: DE
2014-03-25	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2014-03-26	RIN2	Information on inventor provided after grant (corrected)	Inventor name: NEGORO, NOBUYUKI Inventor name: YASUMA, TSUNEO Inventor name: ITOU, MASAHIRO Inventor name: YAMASHITA, MASAYUKI
2014-04-02	RIN2	Information on inventor provided after grant (corrected)	Inventor name: YAMASHITA, MASAYUKI Inventor name: YASUMA, TSUNEO Inventor name: NEGORO, NOBUYUKI Inventor name: ITOU, MASAHIRO
2014-04-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R083 Ref document number: 602007034515 Country of ref document: DE
2014-04-11	REG	Reference to a national code	Ref country code: HR Ref legal event code: T1PR Ref document number: P20140201 Country of ref document: HR
2014-05-05	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20140201 Country of ref document: HR Payment date: 20140505 Year of fee payment: 8
2014-05-22	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20140400473 Country of ref document: GR Effective date: 20140416
2014-06-16	REG	Reference to a national code	Ref country code: EE Ref legal event code: FG4A Ref document number: E009131 Country of ref document: EE Effective date: 20140307
2014-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20140625 Year of fee payment: 8 Ref country code: LT Payment date: 20140519 Year of fee payment: 8 Ref country code: EE Payment date: 20140515 Year of fee payment: 8 Ref country code: MC Payment date: 20140513 Year of fee payment: 8 Ref country code: IE Payment date: 20140610 Year of fee payment: 8
2014-07-31	REG	Reference to a national code	Ref country code: PL Ref legal event code: T3 Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)
2014-08-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GR Payment date: 20140514 Year of fee payment: 8 Ref country code: RO Payment date: 20140513 Year of fee payment: 8 Ref country code: BG Payment date: 20140510 Year of fee payment: 8 Ref country code: CH Payment date: 20140612 Year of fee payment: 8 Ref country code: DE Payment date: 20140618 Year of fee payment: 8 Ref country code: SI Payment date: 20140519 Year of fee payment: 8 Ref country code: PT Payment date: 20140618 Year of fee payment: 8 Ref country code: IS Payment date: 20140507 Year of fee payment: 8 Ref country code: SE Payment date: 20140611 Year of fee payment: 8 Ref country code: AT Payment date: 20140528 Year of fee payment: 8 Ref country code: NL Payment date: 20140510 Year of fee payment: 8 Ref country code: CZ Payment date: 20140605 Year of fee payment: 8 Ref country code: FI Payment date: 20140610 Year of fee payment: 8 Ref country code: LU Payment date: 20140627 Year of fee payment: 8 Ref country code: TR Payment date: 20140528 Year of fee payment: 8 Ref country code: IT Payment date: 20140616 Year of fee payment: 8 Ref country code: ES Payment date: 20140513 Year of fee payment: 8
2014-09-26	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602007034515 Country of ref document: DE
2014-09-29	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E020492 Country of ref document: HU
2014-09-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PL Payment date: 20140429 Year of fee payment: 8 Ref country code: DK Payment date: 20140610 Year of fee payment: 8 Ref country code: LV Payment date: 20140526 Year of fee payment: 8 Ref country code: HU Payment date: 20140613 Year of fee payment: 8
2014-10-03	REG	Reference to a national code	Ref country code: SK Ref legal event code: T3 Ref document number: E 16652 Country of ref document: SK
2014-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20140612 Year of fee payment: 8
2014-10-31	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2014-10-31	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2014-11-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20140609 Year of fee payment: 8 Ref country code: SK Payment date: 20140605 Year of fee payment: 8
2014-12-03	26N	No opposition filed	Effective date: 20140926
2015-01-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602007034515 Country of ref document: DE Effective date: 20140926
2015-01-26	REG	Reference to a national code	Ref country code: DK Ref legal event code: T5 Effective date: 20150119
2015-02-27	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CY Payment date: 20140616 Year of fee payment: 8
2016-01-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602007034515 Country of ref document: DE
2016-01-07	REG	Reference to a national code	Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20151228
2016-01-25	REG	Reference to a national code	Ref country code: DK Ref legal event code: EBP Effective date: 20150630 Ref country code: LT Ref legal event code: MM4D Effective date: 20150626
2016-01-28	REG	Reference to a national code	Ref country code: HR Ref legal event code: PBON Ref document number: P20140201 Country of ref document: HR Effective date: 20150626
2016-01-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 Ref country code: LV Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626
2016-01-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2016-02-02	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2016-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MM01 Ref document number: 646585 Country of ref document: AT Kind code of ref document: T Effective date: 20150626 Ref country code: EE Ref legal event code: MM4A Ref document number: E009131 Country of ref document: EE Effective date: 20150630
2016-02-24	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20150626
2016-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151231 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150627 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151228 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626
2016-03-01	REG	Reference to a national code	Ref country code: SK Ref legal event code: MM4A Ref document number: E 16652 Country of ref document: SK Effective date: 20150626
2016-03-02	REG	Reference to a national code	Ref country code: NL Ref legal event code: MM Effective date: 20150701
2016-03-23	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2016-03-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MT Payment date: 20140812 Year of fee payment: 8
2016-03-31	REG	Reference to a national code	Ref country code: SI Ref legal event code: KO00 Effective date: 20160222
2016-04-01	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20160229
2016-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150701 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 Ref country code: LT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626 Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160101 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626
2016-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150627 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150627 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160112
2016-06-17	REG	Reference to a national code	Ref country code: GR Ref legal event code: ML Ref document number: 20140400473 Country of ref document: GR Effective date: 20160112
2016-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630
2016-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626
2016-12-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630
2017-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626
2017-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150627
2017-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630
2017-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626
2018-01-19	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1150448 Country of ref document: HK
2018-07-10	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20180710
2018-09-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150626

Publication	Publication Date	Title
EP2431367A3 (de)	2012-07-04	Kondensierte cyclische Verbindungen als GPR40 Modulatoren
EP2508524A3 (de)	2012-10-24	Indolverbindung
EP2684861A3 (de)	2014-05-07	Spiroverbindungen und pharmazeutische Verwendung dafür
TW200744588A (en)	2007-12-16	Pharmaceutical composition for external use
MXPA05009356A (es)	2005-12-05	Derivados de c-glicosido y sales de los mismos.
EP2277595A3 (de)	2011-09-28	Verbindungen zur Immunopotenzierung
PL2308942T3 (pl)	2020-01-31	Zastosowanie kompozycji zawierającej trans-1,3,3,3-tetrafluoropropen (trans-HFO- 1234ze) jako czynnik chłodniczy
EA200970726A1 (ru)	2010-02-26	Твердый препарат, содержащий алоглиптин и пиоглитазон
TW200833370A (en)	2008-08-16	Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2006112549A8 (ja)	2007-08-02	縮合複素環化合物
WO2007019255A3 (en)	2007-05-31	Salts of vildagliptin
BRPI0811712A2 (pt)	2014-11-04	"composto, processo de preparação de um composto e composição farmacéutica".
GB0612721D0 (en)	2006-08-09	Organic compounds
EA201000050A1 (ru)	2010-08-30	Замещенные бициклолактамные соединения
EP1905456A4 (de)	2010-12-22	Arzneihaltiges lichtvernetztes hyaluronsäure-derivat-gel
WO2008064353A3 (en)	2008-11-27	7,8-saturated-4,5-epoxy-morphinanium analogs
WO2009020234A3 (en)	2009-04-16	Pyrrolidin-2 -one derivatives as androgen receptor modulator
GB0420344D0 (en)	2004-10-13	Diagnostic compounds
GEP20105033B (en)	2010-06-25	Therapeutic agent for diabetes
EP2388002A3 (de)	2012-01-25	Antidepressivum, das eine heterocylische Verbindung mit einer spezifischen Struktur enthält
EA201000439A1 (ru)	2011-04-29	Бензотиазолы в качестве модуляторов рецептора грелина
MX2010001866A (es)	2010-03-11	Derivados de azoloarina, metodo para su produccion, productos farmaceuticos que contienen estos compuestos y su uso.
IL191680A0 (en)	2009-08-03	Pharmaceutical compositions containing revaprazen or a salt thereof
AR053012A1 (es)	2007-04-18	Polimorfo a de ibandronato
BRPI0417469A (pt)	2007-04-10	bifenil carboxamidas substituìdas com n-aril piperidina